Literature DB >> 21184635

Stereotactic body radiotherapy for spinal metastases: current status, with a focus on its application in the postoperative patient.

Arjun Sahgal1, Mark Bilsky, Eric L Chang, Lijun Ma, Yoshiya Yamada, Laurence D Rhines, Daniel Létourneau, Matthew Foote, Eugene Yu, David A Larson, Michael G Fehlings.   

Abstract

Stereotactic body radiotherapy (SBRT) for spinal metastases is an emerging therapeutic option aimed at delivering high biologically effective doses to metastases while sparing the adjacent normal tissues. This technique has emerged following advances in radiation delivery that include sophisticated radiation treatment planning software, body immobilization devices, and capabilities of detecting and correcting patient positional deviations with image-guided radiotherapy. There are limited clinical data specifically supporting the role of SBRT as a superior alternative to conventional radiation in the postoperative patient. The focus of this review was to examine the evidence pertaining to spine SBRT in the treatment of spinal metastases and to provide a comprehensive analysis of published patterns of failure, with emphasis on the postoperative patient.

Entities:  

Mesh:

Year:  2010        PMID: 21184635     DOI: 10.3171/2010.9.SPINE091005

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  52 in total

1.  Effective local control of vertebral metastases by simultaneous integrated boost radiotherapy: preliminary results.

Authors:  Dorota Lubgan; Anke Ziegaus; Sabine Semrau; Ulrike Lambrecht; Sebastian Lettmaier; Rainer Fietkau
Journal:  Strahlenther Onkol       Date:  2014-11-14       Impact factor: 3.621

Review 2.  Review and uses of stereotactic body radiation therapy for oligometastases.

Authors:  Filippo Alongi; Stefano Arcangeli; Andrea Riccardo Filippi; Umberto Ricardi; Marta Scorsetti
Journal:  Oncologist       Date:  2012-06-20

3.  Delayed vertebral body collapse after stereotactic radiosurgery and radiofrequency ablation: Case report with histopathologic-MRI correlation.

Authors:  Adam N Wallace; Ross Vyhmeister; Andy C Hsi; Clifford G Robinson; Randy O Chang; Jack W Jennings
Journal:  Interv Neuroradiol       Date:  2015-10-23       Impact factor: 1.610

Review 4.  Stereotactic body radiotherapy for the treatment of medically inoperable primary renal cell carcinoma: Current evidence and future directions.

Authors:  Anand Swaminath; William Chu
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

Review 5.  Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress.

Authors:  Paola Jimenez; Claudio Tatsui; Aaron Jessop; Sonali Thosani; Camilo Jimenez
Journal:  Curr Oncol Rep       Date:  2017-10-28       Impact factor: 5.075

6.  The impact of histology and delivered dose on local control of spinal metastases treated with stereotactic radiosurgery.

Authors:  Yoshiya Yamada; Evangelia Katsoulakis; Ilya Laufer; Michael Lovelock; Ori Barzilai; Lily A McLaughlin; Zhigang Zhang; Adam M Schmitt; Daniel S Higginson; Eric Lis; Michael J Zelefsky; James Mechalakos; Mark H Bilsky
Journal:  Neurosurg Focus       Date:  2017-01       Impact factor: 4.047

7.  Is there any role for stereotactic body radiotherapy in the management of metastatic epidural spinal cord compression?

Authors:  Simon S Lo; Charlotte D Kubicky; Eric L Chang; Arjun Sahgal
Journal:  CNS Oncol       Date:  2015

8.  Modern approaches to the management of metastatic epidural spinal cord compression.

Authors:  Zain A Husain; Arjun Sahgal; Eric L Chang; Pejman Jabehdar Maralani; Charlotte D Kubicky; Kristin J Redmond; Charles Fisher; Ilya Laufer; Simon S Lo
Journal:  CNS Oncol       Date:  2017-07-18

Review 9.  Image guidance in spine tumor surgery.

Authors:  Patrick D Kelly; Scott L Zuckerman; Yoshiya Yamada; Eric Lis; Mark H Bilsky; Ilya Laufer; Ori Barzilai
Journal:  Neurosurg Rev       Date:  2019-06-01       Impact factor: 3.042

10.  Interview: Current state of brain and spine radiosurgery and future applications.

Authors:  Arjun Sahgal
Journal:  CNS Oncol       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.